THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration to Advance Oncology Therapeutics.
OUR MISSION

The Cancer Drug Development Forum (CDDF) is the leading non-competitive drug development platform in Europe whose sole objective is to stimulate advancement in cancer drug development and access.

HOW WE ADVANCE OUR MISSION

The CDDF provides a unique platform to facilitate collaboration between stakeholders to increase efficiency in cancer drug development.

Our integrative approach aims to bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to improve cancer treatment.
INITIATIVES

For several years, the Cancer Drug Development Forum (CDDF) has focused on developing initiatives that accelerate effective drug development in oncology treatment and shorten time to market, and time to patient access.

CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into a productive dialogue in a neutral, non-competitive space.

CDDF drives multiple activities and initiatives in collaboration with regulators from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and other regulatory agencies, academic researchers from around the globe, pharmaceutical companies, and patient advocates.

The Cancer Drug Development Forum (CDDF) Spring Conference is a unique annual meeting. This multi-stakeholder, interactive three days meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The responsive nature of the CDDF platform allows programs to be quickly initiated or adapted to reflect current and pressing issues. Following the outbreak of the COVID-19 pandemic, CDDF rapidly organised a webinar to discuss the potential impact of the virus on both cancer care delivery and clinical trial performance.

Since its inception, CDDF has proved to be a visionary force within the cancer drug development field addressing topics such as immuno-oncology, real-world data in cancer drug development, and improving outcomes for children and adolescents with cancer through the ACCELERATE platform launched in 2013.

The CDDF continues to pioneer progress in cancer drug treatments through workshops exploring the potential impact of digital health and artificial intelligence on cancer patients.

CDDF publishes reports prepared from workshops discussions, conference presentations and lecture briefings to increase knowledge of the challenges and opportunities in cancer drug development.
CDDF WORKSHOPS PRESENT REGULATOR, HTA, INDUSTRY, ACADEMIC AND PATIENT PERSPECTIVES. EVERYONE IS GIVEN THE CHANCE TO CONTRIBUTE
CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs.

These distinguished academics, representing a range of perspectives within the drug development process, are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists, who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS

Prof. John Smyth  
Chairperson

Prof. Ruth Plummer  
Deputy Chairperson

Prof. Axel Glasmacher  
Treasurer

Prof. Jaap Verweij  
Board Member and Managing Director

Prof. Francesco De Lorenzo  
Board Member

Prof. Eva Skovlund  
Board Member

Dr Catarina Edfjäll  
Board Member

CDDF OFFICE

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.

Marjorie Recorbet  
Director of Operations

Hyunmin Park  
Association Coordinator

Magdaléna Strmeñová  
Event Coordinator

Giorgia Campagnano  
Event Coordinator
RECENT CDDF ACTIVITIES

The CDDF yearly conference and workshops focus on currently identified issues in cancer care and foster an exchange of expertise to accelerate and deliver cancer treatments.

CONFERENCE

CDDF 11TH YEARLY SPRING CONFERENCE

THE NETHERLANDS | 10-12 FEBRUARY 2020

OBJECTIVES

Understanding the relevance of individual components in combination therapies.

Analysis of progress made in previous CDDF workshop issues: biomarkers; patient access and involvement; Minimal Residual Disease; use of real-world data in drug development.

Understanding advances in, and the need for, innovation and collaboration in tumour agnostic drug-development.

Addressing regulation, progress and challenges in cellular therapies including car-T cell therapies.

Addressing regulatory guidance: EMA regulatory strategy 2025; envisioning product development for 2025; Industry perspectives on innovation and current topics in oncology.

KEY TAKE-HOME MESSAGES FROM THE CONFERENCE

The need to identify the best way forward to speed up drug approval whilst ensuring patient efficiency and safety and avoiding patient discrimination due to limited data on endpoints.

The need to consider the best interests of patients in the drug innovation mission. Agencies must ensure that the benefit-risk balance is positive.

Potential advantages and challenges of project Orbis.
Oncology clinical trial performance has been severely affected by the COVID-19 pandemic. Most researchers have stopped recruitment and the reduction in currently available standard treatments for cancer patients has rendered trial outcomes difficult to assess. Regulatory agencies have already published revised risk assessment guidance.

Leukaemia diagnostics depend on phenotypes and experienced personnel. New options, such as artificial intelligence, machine learning and cloud computing, offer fascinating avenues to achieve better diagnostic accuracy and improved therapeutic selection. This talk demonstrated how these technologies are already used in routine, accredited workflow and how they may change future drug development for haematological malignancies.
WEBINAR

MATCHING ENDPOINTS AND OBJECTIVES IN CLINICAL TRIALS: REFLECTIONS ON DISCONNECTS AND OPPORTUNITIES

WEBINAR | 1 DECEMBER 2020
ARMIN SCHÜLER, MERCK, GERMANY

This webinar assessed the need to contextualise endpoints and objectives and associated opportunities for clinical drug development. Trials often conclude, “The trial met its endpoint”. However, what about the primary objective of the trial? Are the results relevant for stakeholders? Is a clear interpretation of the results possible? The estimands framework, as introduced in ICH E9 (R1), offers a systematic approach to clinical trials design, which answers clinical question more clearly, ultimately leading to a higher probability of success.

WEBINAR

PATIENT ACCESS TO NEWLY REGISTERED ANTICANCER AGENTS

WEBINAR | 9 DECEMBER 2020
PROF. CARIN A. UYL-DE GROOT, ERASMUS UNIVERSITY ROTTERDAM, NETHERLANDS

Many new cancer medicines have been developed that improve patient outcomes. However, access to these agents usually takes longer in Europe than in the United States, and accessibility varies greatly across EU countries. This webinar discussed current access to several recently registered cancer drugs in European countries following EMA marketing authorisation and the implications for patients.
CDDF AGENDA 2021

2021 events focus on current and future challenges impacting cancer drug development

WEBINAR
FROM TREATMENT DEVELOPMENT TO HEALTHCARE: IS THE CONTINUUM BECOMING A REALITY?

DR. DENIS LACOMBE, EORTC, BELGIUM

The needs of patients in healthcare systems should define research priorities. Many questions remain unaddressed when new technologies are approved. Optimising the use of new technologies in healthcare systems, such as (but not limited to), combination, sequence, duration, de-escalation, and adjusting study populations based on clinically validated biomarkers, requires robust datasets addressing medically relevant endpoints. Multidisciplinary, pragmatic clinical research addressing such questions, traditionally performed by the non-commercial sector, is the cornerstone of treatment development and access. Delivering datasets informative to patients, doctors, HTA bodies, and investors should be integral to the process of providing treatment to the healthcare system to address the efficacy-effectiveness gap. Re-engineering the process while integrating new solutions for data access depends partly on the methodological and economic challenges addressed during the Webinar.

VIRTUAL CONFERENCE
CDDF 12TH SPRING CONFERENCE

OBJECTIVES

To understand the pitfalls in the European HTA process leading to current inequality in patient access.

To move the debate on endpoints in cancer clinical trials, digital tools and the use of artificial intelligence in cancer drug development forward constructively.

To understand current differences in global regulatory approval and HTA approaches and discuss the potential for harmonisation.

To raise awareness on novel methods in clinical oncology imaging, and discussion on their application as biomarkers in the drug development process.

To address regulatory guidance: EMA regulatory strategy 2025; envisioning product development for 2025; Industry perspectives on innovation and current topics in oncology.
OBJECTIVES
To understand past achievements and current challenges in the definition and assessment of endpoints.

To update knowledge on novel endpoints, such as measurable residual disease and circulating tumour nucleotides, and identify possible pathways for validation.

To understand strategies and overcome obstacles to increase the use of patient-reported outcomes in cancer drug development.

To develop awareness of the need to use endpoints in expedited regulatory pathways.

ONLINE WORKSHOP
ENDPOINTS IN CANCER DRUG DEVELOPMENT

ONLINE WORKSHOP | 26 - 28 APRIL 2021

KEY TAKE-HOME MESSAGES FROM THE CONFERENCE
The multi-stakeholder set-up is considered as one of the assets of CDDF meetings.

Active involvement of the patient voice and the patient-centred approach, are crucial. Continued training of patient advocates is important.

Tumour agnostic aspects will be the center of many future activities.

Real time oncology review (FDA-RTOR) was enthusiastically welcomed. Lessons can also be learned from the rolling reviews of COVID-vaccine trials.

The development of a Forum to discuss unequal access to drugs, received a lot of support.
OBJECTIVES
To understand the current landscape of digital tool use in cancer drug development.
To explore regulatory aspects, challenges and plans for the formal registration of digital tools from trial data.
To understand existing digital options to support trials and improve data collection and outcomes.

FOOTCOURING WEBINARS
The CDDF plans a series of webinars in 2021 to further address hot topics surrounding the oncology drug development, such as lessons learned from COVID-19, ctDNA and solid tumours, endpoints in clinical trials, European pharmaceutical strategies and patient access to cancer drugs.

PLANNED DISCUSSIONS AND ACTIVITIES IN 2022
Spring Conference, 7 to 9 February 2022 in Noordwijk aan Zee, The Netherlands
- Workshop on MRD/ctDNA
- Workshop on patient engagement and access in oncology drug development
- Workshop on tissue-agnostic drug development: consequences for regulatory and health-technology assessment
CDDF INDUSTRY PARTNERS PLATFORM

WHAT IS THE CDDF INDUSTRY PARTNERS PLATFORM?

The CDDF Industry Partners Platform is composed of large and SME partners from the pharmaceutical industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Partners Platform acts as an advisory body within CDDF. It supports the association in compliance with all relevant regulations in a manner consistent with the non-competitive, non-commercial platform that CDDF offers to all stakeholders.

WHY JOIN THE CDDF INDUSTRY PARTNERS PLATFORM?

- Stimulate advancement in oncology treatment and delivery
- Identify and overcome challenges in the development of cancer drugs
- Improve product time to market for new treatments

CONTRIBUTE TO THE DEVELOPMENT OF CANCER DRUGS AND TREATMENT
BECOME A PARTNER OF THE CDDF

INDUSTRY PARTNER BENEFITS

1. **Access to the CDDF Industry Partners Platform** where pharmaceutical partners meet to discuss industry perspectives on the challenges of cancer drug development.

2. **Complimentary registrations to every CDDF event** (see details in the partnership package).

3. **Livestream access** to CDDF workshops and conference on the condition that at least two delegates (or one SME delegate) are present in person at the event.

4. **Early access to digital content** from the conference and workshops for one year before general release.

5. **Opportunity to contribute to CDDF’s scientific programme** and coordinate event programmes alongside academics and regulators.

6. Access to a **reputable oncology network** and occasions to connect informally with representatives from academia, regulatory authorities, HTAs, and patient groups.
### CDDF INDUSTRY PARTNERSHIP PACKAGES

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Start-up Small business</th>
<th>Medium-sized enterprise</th>
<th>Large pharmaceutical company</th>
</tr>
</thead>
<tbody>
<tr>
<td>No oncology product on the market AND Revenues ≤ € 50 million</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
</tr>
<tr>
<td>Either low revenues w/ at least one oncology product on the market or medium or large revenues w/ no oncology product on the market</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
</tr>
<tr>
<td>At least one oncology product on the market AND Revenues ≥ € 1 billion</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
<td>✓ Yes</td>
</tr>
</tbody>
</table>

| Annual Contribution | € 7 000 | € 18 000 | € 40 000 |

### BENEFITS

- Access the CDDF Industry Partners Platform: ✓ Yes, ✓ Yes, ✓ Yes
- Free registration to every CDDF event: 1, 2, 4
- Livestream access to CDDF workshops and conference*: ✓ Yes, ✓ Yes, ✓ Yes
- Early access to digital content from the conference and workshops for one year before release: 5, 15, unlimited
- Contribute to CDDF’s scientific programme and coordinate event programmes: ✓ Yes, ✓ Yes, ✓ Yes

* on the condition that at least two delegates (or one SME delegate) are present in person at the event.
COLLABORATION IS THE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS